Literature DB >> 10446918

Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning.

R D Huhn1, J F Tisdale, B Agricola, M E Metzger, R E Donahue, C E Dunbar.   

Abstract

The ability to engraft significant numbers of genetically modified hematopoietic stem and progenitor cells without the requirement for fully myeloablative conditioning therapy is a highly desirable goal for the treatment of many nonmalignant hematologic disorders. The aims of this study were to examine, in nonhuman primates (rhesus), (1) the effects of pretreatment of host animals with cytokines (G-CSF and SCF), i.e., before nonmyeloablative irradiation, on the degree and duration of neo gene marking of circulating leukocytes after autologous cell reinfusion and (2) to compare transduction of primitive hematopoietic target cells in the presence of our standard transduction cytokine combination of IL-3, IL-6, and stem cell factor (SCF) and in the presence of an alternative combination containing SCF, G-CSF, and the thrombopoietin analog MGDF. Cytokine-mobilized rhesus peripheral blood progenitor/stem cells (PBSCs) were enriched for CD34+ cells and transduced with neo vectors (either G1Na or LNL6) for 96 hr in cultures containing rhIL-3, rhIL-6, and rhSCF or MGDF, rhSCF, and rhG-CSF and cryopreserved. Four animals underwent minimal myeloablative conditioning with 500 cGy irradiation with or without pretreatment with SCF and G-CSF, followed by reinfusion of the cryopreserved cells on the subsequent day. Neutrophil nadirs (< or =500/mm3) were 0-3 days in duration; there were no significant periods of severe thrombocytopenia. Marking of circulating granulocytes and mononuclear cells was extensive and durable in all animals (exceeding 12% in the mononuclear cells of one animal) and persisted beyond the final sampling time in all animals (up to 33 weeks). No difference in extent or duration of marking was attributable to either cytokine presensitization of recipients prior to irradiation, or to the substitution of MDGF and G-CSF for IL-3 and IL-6 during transduction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446918     DOI: 10.1089/10430349950017464

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  12 in total

1.  Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model.

Authors:  C Berger; M L Huang; M Gough; P D Greenberg; S R Riddell; H P Kiem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells.

Authors:  Jonathan M Hill; Alexander J Dick; Venkatesh K Raman; Richard B Thompson; Zu-Xi Yu; K Allison Hinds; Breno S S Pessanha; Michael A Guttman; Timothy R Varney; Bradley J Martin; Cynthia E Dunbar; Elliot R McVeigh; Robert J Lederman
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

Review 3.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

4.  Impact of irradiation and immunosuppressive agents on immune system homeostasis in rhesus macaques.

Authors:  C Meyer; J Walker; J Dewane; F Engelmann; W Laub; S Pillai; Charles R Thomas; I Messaoudi
Journal:  Clin Exp Immunol       Date:  2015-06-29       Impact factor: 4.330

Review 5.  Gene therapy of chronic granulomatous disease: the engraftment dilemma.

Authors:  Manuel Grez; Janine Reichenbach; Joachim Schwäble; Reinhard Seger; Mary C Dinauer; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-11-02       Impact factor: 11.454

Review 6.  Contributions of gene marking to cell and gene therapies.

Authors:  Cecilia N Barese; Cynthia E Dunbar
Journal:  Hum Gene Ther       Date:  2011-05-05       Impact factor: 5.695

7.  Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates.

Authors:  M Takatoku; S Sellers; B A Agricola; M E Metzger; I Kato; R E Donahue; C E Dunbar
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

8.  Modeling promising nonmyeloablative conditioning regimens in nonhuman primates.

Authors:  Devikha Chandrasekaran; Betty Nakamoto; Korashon L Watts; Hans-Peter Kiem; Thalia Papayannopoulou
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

9.  Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.

Authors:  Alessandro Aiuti; Immacolata Brigida; Francesca Ferrua; Barbara Cappelli; Robert Chiesa; Sarah Marktel; Maria-Grazia Roncarolo
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

10.  Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts.

Authors:  Matthew M Hsieh; Saskia Langemeijer; Aisha Wynter; Oswald A Phang; Elizabeth M Kang; John F Tisdale
Journal:  Exp Hematol       Date:  2007-07-09       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.